Notification of trade in relation to reverse share split

Reference is made to the stock exchange notice on 26 May 2011 related to DiaGenic’s reverse share split in the ratio 10:1. Some of the Company’s shareholders owned a number of shares that could not be divided by 10, and these are rounded up to the nearest whole share after the reverse share split. The Company had agreed with insider Erik Christensen that he will free of compensation provide the number of shares that that such rounding off will entail. Today the reverse share split has been settled and Erik Christensen cedes 338 shares in DiaGenic. Post this transaction Erik Christensen owns 10,300 shares in DiaGenic.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com